Q2 2026 saw 4% revenue growth to $487.8M, with net income of $39.8M and Adjusted EBITDA of $76.4M. Same-unit reimbursement improved, but patient volume declined. Full-year Adjusted EBITDA guidance remains $280M–$300M.Original document: Pediatrix Medical Group, Inc. [MD] SEC 8-K Current Report — Aug…
Q2 2026 saw 4% revenue growth to $487.8M, with net income of $39.8M and Adjusted EBITDA of $76.4M. Same-unit reimbursement improved, but patient volume declined. Full-year Adjusted EBITDA guidance remains $280M–$300M.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
